Vai al contenuto principale
xMedica

NCT07624305ClinicalTrials.gov

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered…

Fase 32800 partecipanti ricercati478 centri27 paesi

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-06-03; recorded start 2026-09-01
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type10/10

    Mortality / MACE endpoint (hard clinical outcome)

  • Multi-centre8/8

    Multi-centre: 45 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,800 participants (target), run at 478 sites, across 27 countries.

How this score is built
  • Enrolment34/40

    2,800 participants (target)

  • Site count19/25

    45 sites

  • Country count12/15

    8 countries

  • Planned duration9/10

    Planned over about 47 months

  • Sponsor scale10/10

    AstraZeneca has led 999 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from interventional trials.

This is a Phase III, multicentre, randomised, double-blind, double-dummy, parallel-group, active-controlled, event-driven study in participants with CKD Stage 3b and 4. The purpose of this study is to determine if balcinrenone/dapagliflozin, compared with dapagliflozin, administered as a capsule once daily on a background of standard of care (SoC) therapy, reduces the risk of CV death, death from kidney failure, kidney failure, sustained ≥ 50% decline from baseline in eGFR, and HF events in adults with CKD Stage 3b and 4. The study will also assess safety and tolerability of balcinrenone/dapagliflozin. Eligible patients will randomly be assigned with a 1:1 ratio to receive once daily administration of one capsule and one tablet of one of the following treatments: 1. Balcinrenone/dapagliflozin 15 mg/10 mg capsule and matching placebo for dapagliflozin 10 mg tablet 2. Dapagliflozin 10 mg tablet and matching placebo for balcinrenone/dapagliflozin capsule The study will be conducted at approximately 550 sites in approximately 30 countries, globally.

Patologie

  • Renal Insufficiency, Chronic

Idoneità

Idoneità
SessoTutti
Età18 Years – 99 Years
Volontari saniNo

Idoneità come riportata nel registro

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of CKD and at least one of the following: 1. eGFR ≥ 15 to \< 45 mL/min/1.73 m2 AND: UACR ≥ 30 mg/g (central laboratory) or UACR ≥ 100 mg/g (local laboratory ) or UPCR ≥ 200 mg/g (local laboratory). 2. eGFR ≥ 15 to \< 30 mL/min/1.73 m2 and UACR \< 30 mg/g (local or central laboratory UACR value). * Serum/plasma K+ ≤ 5.0 mmol/L * Maximum tolerated dose of an ACEi or an ARB, unless contraindicated or not tolerated. The dose should be stable for at least 4 weeks before screening. Exclusion Criteria: * Recent (within 90 days prior to screening) or ongoing dialysis, or likely to require dialysis within 3 months following randomisation * UACR ≥ 5000 mg/g or UPCR ≥ 7000 mg/g at screening. * SBP \> 180 mmHg or DBP \> 110 mmHg at screening. * SBP \< 90 mmHg at screening. * HbA1c \> 9% at screening * T1DM, except: 1. For US only: patients with T1DM treated with SGLT2i for at least 4 months prior to screening, without DKA during that period, and who have experience with ketone monitoring are eligible. 2. For Japan only: patients with T1DM treated with dapagliflozin 10 mg for at least 4 months prior to Screening, without DKA during the period of dapagliflozin treatment are eligible for inclusion. * Autosomal dominant polycystic kidney disease. * Major cardiac or valvular surgery, acute coronary syndrome (myocardial infarction or unstable angina), stroke, transient ischaemic attack within 12 weeks prior to screening. * Severe hepatic impairment (Child-Pugh Class C). * Adrenal insufficiency. * Clinically significant acute kidney injury within 12 weeks prior to the screening. * New York Heart Association functional HF class IV at screening, or hospitalisation for heart failure within 4 weeks prior to screening. * Any clinical condition requiring systemic immunosuppression therapy other than maintenance therapy (stable for at least 3 months) prior to screening. * Solid organ or bone marrow transplant or a plan for transplant within 6 months following randomisation. * Any use of the following medications and supplements: 1. MRAs 2. Aldosterone analogues 3. Aldosterone synthase inhibitors 4. Any use of potassium binders within 2 weeks prior to screening. Use is allowed after randomisation. 5. Strong or moderate inducers or inhibitors of CYP3A4, prohibited at least one week prior to randomisation

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioInterventistico
FaseFase 3
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoQUADRUPLE (4)
Arruolamento2800 partecipanti ricercati

Sponsor e collaboratori

  • AstraZeneca Sponsor

Bracci e interventi

  • Balcinrenone/dapagliflozinEXPERIMENTAL

    Patient receives once daily 1 capsule balcinrenone 15 mg and dapagliflozin 10 mg and 1 placebo tablet matching dapagliflozin.

  • DapagliflozinACTIVE_COMPARATOR

    Patient receives once daily 1 placebo capsule matching balcinrenone and dapagliflozin and 1 tablet dapagliflozin 10 mg.

Interventi

  • Farmaco Balcinrenone/dapagliflozin

    balcinrenone/dapagliflozin 15 mg/10 mg

  • Farmaco Dapagliflozin

    dapagliflozin 10 mg

  • Farmaco Placebo matching Dapagliflozin

    matching placebo for dapagliflozin 10 mg

  • Farmaco Placebo matching balcinrenone/dapagliflozin

    matching placebo for balcinrenone/dapagliflozin

Esiti misurati

  1. Esito primario

    Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure, sustained 50% or greater decline in eGFR, and heart failure event

    Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure * Initiation of maintenance dialysis or * Kidney transplantation * Sustained ≥ 50% decline from baseline in eGFR * HF with or without hospitalisation

    Orizzonte temporale Up to 46 months.

  2. Esito secondario

    Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure and sustained 50% or greater decline in eGFR.

    Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure: * Initiation of maintenance dialysis or * Kidney transplantation Sustained ≥ 50% decline from baseline in eGFR

    Orizzonte temporale Up to 46 months.

  3. Esito secondario

    Change in urinary albumin to creatinine ratio to Week 24

    Change from baseline to Week 24 in urinary albumin to creatinine ratio

    Orizzonte temporale Baseline to Week 24

  4. Esito secondario

    Time to first occurrence of cardiovascular death or heart failure event.

    Time from randomization to first occurrence of any of the components of the composite: * CV death * HF with or without hospitalisation

    Orizzonte temporale Up to 46 months.

  5. Esito secondario

    Time to cardiovascular death

    Time from randomization to cardiovascular death.

    Orizzonte temporale Up to 46 months.

  6. Esito secondario

    Time to death from any cause

    Time from randomization to death from any cause.

    Orizzonte temporale Up to 46 months.

Date

Date
Data di inizio1 settembre 2026 (effettiva)
Conclusione primaria1 luglio 2030 (stimata)
Conclusione1 luglio 2030 (stimata)
Prima pubblicazione3 giugno 2026 (effettiva)
Ultimo aggiornamento24 settembre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltasettembre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

33 centri stanno reclutando

Argentina

Argentina
StrutturaCittàStato o regioneStato
Research SiteCABANon ancora in reclutamento
Research SiteCapital FederalNon ancora in reclutamento
Research SiteCiudad de Buenos AiresNon ancora in reclutamento
Research SiteLa PlataNon ancora in reclutamento
Research SiteLanús EsteNon ancora in reclutamento
Research SiteMar del PlataNon ancora in reclutamento
Research SiteRosarioNon ancora in reclutamento
Research SiteRosarioNon ancora in reclutamento
Research SiteRosarioNon ancora in reclutamento
Research SiteSan NicolásNon ancora in reclutamento
Research SiteSanta FeNon ancora in reclutamento
Research SiteSanta FeNon ancora in reclutamento

Austria

Austria
StrutturaCittàStato o regioneStato
Research SiteFeldkirchNon ancora in reclutamento
Research SiteInnsbruckNon ancora in reclutamento
Research SiteLinzNon ancora in reclutamento
Research SiteSankt PöltenNon ancora in reclutamento
Research SiteViennaNon ancora in reclutamento
Research SiteViennaNon ancora in reclutamento
Research SiteViennaNon ancora in reclutamento
Research SiteViennaNon ancora in reclutamento
Research SiteWelsNon ancora in reclutamento
Research SiteWiener NeustadtNon ancora in reclutamento

Brazil

Brazil
StrutturaCittàStato o regioneStato
Research SiteBarretosNon ancora in reclutamento
Research SiteBelo HorizonteNon ancora in reclutamento
Research SiteBelo HorizonteNon ancora in reclutamento
Research SiteBelémNon ancora in reclutamento
Research SiteCampinasNon ancora in reclutamento
Research SiteGoiâniaNon ancora in reclutamento
Research SiteNatalNon ancora in reclutamento
Research SiteRecifeNon ancora in reclutamento
Research SiteSão Caetano do SulNon ancora in reclutamento
Research SiteSão José do Rio PretoNon ancora in reclutamento
Research SiteSão José dos CamposNon ancora in reclutamento
Research SiteSão PauloNon ancora in reclutamento
Research SiteSão PauloNon ancora in reclutamento
Research SiteSão PauloNon ancora in reclutamento
Research SiteSão PauloNon ancora in reclutamento

Bulgaria

Bulgaria
StrutturaCittàStato o regioneStato
Research SiteBlagoevgradNon ancora in reclutamento
Research SiteNova ZagoraNon ancora in reclutamento
Research SitePlevenNon ancora in reclutamento
Research SitePlovdivNon ancora in reclutamento
Research SiteSandanskiNon ancora in reclutamento
Research SiteSevlievoNon ancora in reclutamento
Research SiteSofiaNon ancora in reclutamento
Research SiteSofiaNon ancora in reclutamento
Research SiteSofiaNon ancora in reclutamento
Research SiteStara ZagoraNon ancora in reclutamento
Research SiteVarnaNon ancora in reclutamento

Canada

Canada
StrutturaCittàStato o regioneStato
Research SiteBramptonOntarioNon ancora in reclutamento
Research SiteCalgaryAlbertaRitirato

Nella scheda del registro sono indicati altri 428 centri.

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 24 settembre 2026

    Stato modificato

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  2. 24 settembre 2026

    Reclutamento aperto

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  3. 24 settembre 2026

    Centro aggiunto

    433 sites added (478 total)

    45478